Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry

Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry

Survival rates for HB patients have improved; however, outcomes for patients who relapse remain poor. A retrospective review of information gathered for the HB99 study and the German Liver Tumor Registry identified 25 relapse patients (6.9%, 25/362). The median time from initial diagnosis to first r...

Full description

Bibliographic Details
Main Authors: Rebecca Maxwell, Beate Häberle, Roland Kappler, Dietrich von Schweinitz, Mark Rassner, Julia von Frowein, Irene Schmid
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
hepatoblastoma
relapse
AFP
irinotecan
Online Access:https://www.mdpi.com/2072-6694/16/4/696

Internet

https://www.mdpi.com/2072-6694/16/4/696

Similar Items